Krebs Biochem (KREBSBIO)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹54.6 |
| Market Cap | ₹117.72 Cr |
| P/E Ratio | 0 |
| ROCE | -30.09% |
| ROE | 17.57% |
| Dividend Yield | 0% |
| Profit Growth | 59.56% |
| Debt/Equity | — |
| Sales Growth | 27.4% |
| Promoter Holding | 72.74% |
| 52-Week Range | ₹38.33 — ₹76.85 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹-75.83 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
A balance sheet with negative book value is a red flag I cannot ignore. Krebs Biochem has Book Value of ₹-74.59 per share, meaning liabilities exceed assets. The P/E of 0.00 and P/B 'N/A' are not glitches; they are the market telling you that earnings don't exist and equity is gone. In the latest quarter, sales were only ₹7 Cr and net profit was ₹-3 Cr. That is a heavy loss on a small revenue base. Full-year sales have declined 36.62%, so the franchise is shrinking, not compounding. ROCE of -30.09% means every rupee deployed in the business is being destroyed. The reported ROE of 17.57% is a mathematical oddity caused by dividing a loss by negative book value; it is not genuine shareholder return. At ₹59.46, the company commands a ₹123 Cr market cap for a business that is losing money and has negative equity—there is no earnings yield to justify that price.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer